Stock Region Research Report
Deep Value, Radical Pivots, and Autonomy
Stock Region Weekly Watchlist: Deep Value, Radical Pivots, and Autonomy
The stocks featured in this report were previously delivered in our trading room in real-time. To access Stock Region’s real-time trade ideas, then be sure to purchase a membership now.
DISCLAIMER: Each of Stock Region University LLC’s services, products, and site are available for informational and educational purposes only. None of the information contained in this publication constitutes, or is intended to constitute, a recommendation of any particular security or trading strategy or a determination that any security or trading strategy is suitable for any specific person. Stock Region University LLC is not a registered investment professional nor financial advisor. This is not investment or financial advice. All information or advice shown is used for educational purposes only. Moderator commentary is opinion and ideas only and does not constitute any recommendation whatsoever. Participants are trading at their own risk. By engaging with this content, the reader is solely agreeing to this disclaimer.
The Market Landscape: A Shift Toward Strategic Realities
As the final week of July 2026 unfolds, the broader equities market is experiencing a profound recalibration. Capital is rotating aggressively out of speculative momentum plays and seeking refuge in companies with tangible assets, sovereign supply chain backing, and aggressive survival strategies. The era of cheap capital is decisively over, and the market is now demanding proof of concept, immediate commercialization, or radical corporate restructuring to justify valuations. The emotional whiplash in the micro-cap and small-cap sectors is palpable, characterized by violent price swings, forced reverse splits, and highly unconventional capital allocation strategies.
This edition of the Stock Region watchlist dives deep into five unique equities that embody the extreme volatility and immense opportunity of the current market environment. These are not passive index constituents; these are battleground stocks. From a domestic critical minerals supplier issuing a surprise special dividend to force a market revaluation, to a clinical-stage biotech company executing one of the most astonishing corporate pivots in recent memory by transforming into a green hydrogen producer, the narratives here are intense and complex.
The analysis presented here is an exhaustive, opinionated deconstruction of the financial engineering, technological breakthroughs, and geopolitical undercurrents driving these specific equities. The market often acts irrationally in the short term, heavily punishing companies for necessary strategic shifts or entirely ignoring massive government-backed funding. For the astute observer, this irrationality is exactly where the strategic advantage lies.
Below is an exhaustive examination of American Resources Corporation ($AREC), Exyn Technologies ($EXYN), Maison Solutions ($MSS), Autonomix Medical ($AMIX), and Matinas BioPharma ($MTNB).
American Resources Corporation ($AREC): The Sum-of-the-Parts Screaming Buy
It is frankly astounding to witness the broader financial markets completely overlook the strategic repositioning of American Resources Corporation ($AREC). Trading near the $1.80 mark with a market capitalization hovering between $189 million and $197 million, this company represents a masterclass in asset unbundling and geopolitical opportunism. On July 24, 2026, the company’s Board of Directors dropped a highly unconventional bombshell: the declaration of a special cash dividend of $0.0431 per share, payable on August 25, 2026, to shareholders of record as of August 15, 2026.
Why would a growth-oriented, critical minerals company issue a cash dividend instead of hoarding every available dollar for capital expenditures? The answer lies in sheer frustration with market mispricing. The Board of Directors effectively utilized this dividend, alongside a recently authorized share repurchase program, to signal absolute confidence in the company’s $72.5 million cash and short-term investments position, forcing the market to recognize the sum-of-the-parts valuation that is currently being ignored [cite: 1, 5]. CEO Mark Jensen has made it abundantly clear that the market’s assessment of$AREC does not reflect the underlying value of its strategic investments, majority-owned subsidiaries, or its legacy coal-based critical mineral initiatives.
The ReElement Technologies Juggernaut
To understand the severe undervaluation of $AREC, one must deeply analyze its underlying assets, primarily its roughly 19% strategic minority ownership interest in ReElement Technologies. ReElement is not just another speculative mining concept; it is a fully commercialized, domestic refining powerhouse that utilizes patented Ligand-Assisted Displacement (LAD) chromatography.
Developed over four decades at Purdue University by Dr. Linda Nien-hwa Wang and advanced by ReElement’s Chief Technology Officer, Dr. Yi Ding, LAD chromatography completely upends the traditional refining paradigm. Legacy critical mineral refining relies on highly toxic, environmentally disastrous, and massive-footprint solvent extraction methods, a sector in which China currently controls over 90% of global capacity. The ReElement process is modular—engineered to fit into standard shipping containers for decentralized deployment—and utilizes specialized resins to achieve unprecedented purity levels without harsh chemicals.
The technical achievements of this platform are staggering. Dr. Ding’s research and ReElement’s commercial execution have proven capable of producing greater than 99.5% pure rare earth oxides—specifically the highly coveted “magnet REEs” neodymium (Nd), praseodymium (Pr), dysprosium (Dy), and terbium (Tb)—from end-of-life permanent magnets. Furthermore, the platform has produced 99.9978% pure, battery-grade lithium carbonate (Li2CO3) from lithium-ion battery manufacturing waste and spodumene ores.
The geopolitical implications of this technology have triggered a massive influx of sovereign capital. The U.S. government views the domestication of the Neodymium Iron Boron (NdFeB) magnet supply chain as an existential national security imperative. Consequently, ReElement has become a primary beneficiary of federal industrial policy:
Department of War ($25M): ReElement recently secured a $25 million investment from the Department of War’s Industrial Base Fund to expand its refining capacity in Marion, Indiana, accelerating the production of heavy rare earths for defense and aerospace applications.
Office of Strategic Capital ($80M): The OSC announced an $80 million conditional loan commitment to ReElement as part of a joint $700 million package with Vulcan Elements. The goal is to produce up to 10,000 metric tons of NdFeB magnet material in the coming years, utilizing funding from the recently passed One Big Beautiful Bill Act (OBBBA).
National Science Foundation ($160M Consortium): ReElement was named the key industry partner in the “Critical Materials Crossroads” Regional Innovation Engine, led by the University of Missouri-Kansas City, which is eligible for up to $160 million in NSF funding over the next decade.
Financially, ReElement recently closed a U.S.-focused private capital investment round featuring a $150 million pre-money valuation [cite: 21]. Simple mathematics dictates that$AREC’s 19% retained stake in ReElement alone is worth nearly $30 million, providing a massive floor to$AREC’s valuation.
Electrified Materials (EMCO) and Legacy Assets
Beyond the minority stake in ReElement, $AREC holds majority ownership of Electrified Materials Corp. (EMCO). EMCO serves as the company’s direct, consolidated operating platform focused on the aggregation, recovery, and preprocessing of end-of-life batteries and magnets.
On July 16, 2026, EMCO closed a highly strategic $9.5 million Series A Convertible Preferred Stock private placement at $25.00 per share (378,200 shares) [cite: 4]. While the market reacted poorly to this news—sending$AREC shares down 12.64% and stripping $29 million from its market cap due to fears of eventual equity dilution—the terms of the deal indicate significant institutional faith in the subsidiary. The preferred shares include a conversion mechanism based on an 85% discount to an initial go-public listing price, or a hard $125.0 million valuation cap upon a potential spin-out or public offering.
Add to this the company’s legacy coal-based critical mineral byproduct initiatives. On July 9, 2026, $AREC announced it was selected by the U.S. Department of Energy (DOE) for award negotiations under a $75 million “Mines & Metals Capacity Expansion” funding program. This consortium-based project will utilize ReElement’s chromatographic separation to extract critical materials from coal refuse and industrial byproducts, turning environmental liabilities into strategic assets.
The perspective taken by this analysis is that $AREC is a deeply undervalued, fundamentally misunderstood holding company. Retail investors and algorithmic traders are punishing the stock for complex corporate structuring (the deconsolidation of ReElement and the EMCO preferred placement) while entirely missing the forest for the trees. The special dividend is a bold, aggressive maneuver by management to reward long-term shareholders and force the market to recognize that the combined value of a $150M-valued ReElement, a $125M-capped EMCO, $72M in cash, and massive federal backing far exceeds the current $1.80 share price.
Exyn Technologies ($EXYN): Autonomy Enters the Defense Sustainment Behemoth
When observing the trajectory of Exyn Technologies ($EXYN), one is struck by the severe disconnect between the company’s technological milestones and its dismal stock price performance. Following a recent public listing on the Nasdaq, the stock has been battered, dropping over 49% year-to-date and 54% in the last month alone, hovering near the $3.00 level with a microscopic market capitalization of roughly $24.4 million. The market reaction has been brutally pessimistic, treating the company as a failed SPAC or a novelty hardware play. Yet, the underlying business is executing a strategic expansion into the military-industrial complex that borders on genius.
On July 24, 2026, Exyn Defense (the company’s dedicated defense subsidiary formed in late 2024) announced a massive strategic pivot: expanding its field-proven AI autonomy from operational battlefield missions directly into the multi-billion-dollar defense sustainment and readiness market.
The Organic Industrial Base (OIB) Opportunity
To fully grasp the magnitude of this pivot, one must understand the fiscal realities of the Department of Defense’s Organic Industrial Base (OIB). The OIB consists of the depots, shipyards, arsenals, and maintenance facilities that keep military assets mission-ready. While the procurement of new fighter jets and submarines garners the headlines and the majority of public attention, the reality of military budgeting is much more heavily weighted toward maintenance. According to the U.S. Government Accountability Office, sustainment (operating and support) represents roughly 70% of a weapon system’s total lifecycle cost.
This is a budget-backed, perpetual revenue stream that is utterly desperate for modernization, especially as the 2026 DoD budget requests emphasize supply chain security and OIB modernization under the National Defense Industrial Strategy. Exyn Defense is bypassing the highly crowded, hyper-competitive combat drone space and inserting itself directly into the unglamorous, highly lucrative world of military maintenance.
Exyn Defense is scheduled to launch its first aircraft sustainment deployment at the U.S. Air Force’s Warner Robins Air Logistics Complex, in partnership with Asylon Robotics. The timeline is incredibly aggressive for a defense contractor: a Minimum Viable Product (MVP) demonstration is slated for October 2026, with planned operational activities commencing in January 2027.
ExynAI and Nexys: True Level 4B Autonomy
The technology underpinning this massive logistical deployment is the ExynAI autonomy engine, paired with the Nexys autonomous mapping system. Exyn, a spin-out from the renowned GRASP Laboratory at the University of Pennsylvania, is a pioneer in Level 4B autonomous navigation. This is not simplistic waypoint flying. Level 4B means their aerial and ground robots can operate in complex, GPS-denied, and communications-denied environments without prior maps, external infrastructure, or continuous human control.
At Warner Robins, this technology will not be used for battlefield reconnaissance; it will be used for autonomous aircraft inspection and cargo mapping. By utilizing perception-driven navigation and onboard AI, the Nexys platform can navigate the intricate, scaffolding-filled environments of an aircraft depot to capture high-fidelity 3D digital twins of aircraft components. The strategic objective is to radically reduce inspection times, eliminate manual data entry errors, and return critical assets to operational service significantly faster, thereby directly increasing combat readiness.
Furthermore, Exyn is currently pushing its Nexys platform through the U.S. government’s Green UAS certification process. This certification is a critical procurement framework that emphasizes secure, trusted, and interoperable autonomous systems, essentially pre-clearing the technology for widespread adoption across federal agencies and public safety programs. Exyn also recently secured a Vendor Loan Agreement with USSOCOM through its subsidiary Range, further cementing its integration into the DoD ecosystem.
Despite this profound TAM expansion, the sentiment surrounding $EXYN remains overwhelmingly negative. On the day of the Warner Robins announcement, the market sold the news, driving the stock down 3.09% on massive volume (80.3x relative volume), with momentum scanners triggering 79 alerts as the stock swung between a peak of +38.5% and a trough of -25.9% intraday.
The perspective taken by this analysis is that the market is entirely mispricing Exyn’s transition from a niche commercial/battlefield robotics provider to an enterprise-level defense sustainment partner. The OIB is famously inefficient, reliant on manual labor and legacy tracking systems. If Exyn’s Level 4B autonomy can shave even a fraction of a percent off the 70% lifecycle sustainment costs of U.S. Air Force assets, the recurring software and hardware revenue potential for this $24 million market-cap company is staggering. The current stock price reflects extreme short-term impatience and a misunderstanding of defense procurement cycles, completely masking the long-term, budget-backed integration currently underway.
Maison Solutions ($MSS): A Desperate, Brilliant Pivot into Grocery AI
The retail sector is notoriously brutal, and the Asian specialty grocery market is no exception. Maison Solutions ($MSS), a California-based grocer, has found itself in a desperate fight for its corporate life. Trading at around $1.84, the company has suffered a devastating year, culminating in a 1-for-5 reverse stock split executed on July 22, 2026, to maintain compliance with Nasdaq’s $1.00 minimum bid price rule and avoid immediate delisting.
When a micro-cap company executes a reverse split and begins liquidating core assets—such as Maison’s recent July 3, 2026 agreement to divest its loss-generating San Gabriel and Monrovia store operations for a mere $4.5 million—the traditional market reaction is to assume imminent bankruptcy. Indeed, analyst sentiment has been overwhelmingly negative, pointing to weak fundamentals, razor-thin 20% gross margins on $124 million in revenue, negative EBIT margins, and a highly unattractive position relative to broader consumer staples peers.
However, hidden beneath the financial carnage of store closures, reverse splits, and plummeting share prices is a survival strategy that is as radical as it is fascinating. Maison Solutions is not just closing stores; it is attempting a complete technological metamorphosis. On July 24, 2026, Maison Solutions signed a definitive agreement to establish Maison AI Limited, a technology platform entirely focused on artificial intelligence applications specifically designed for grocery retail, supply-chain management, and enterprise operations.
The AI-Native Grocery Supply Chain
This is not merely a buzzword-compliant rebrand designed to artificially inflate the stock price. Maison Solutions will own 90.09% of Maison AI Limited through its wholly-owned subsidiary AZLL LLC, maintaining strict strategic and operational control over the new entity. The company is taking its proprietary merchandise-display planning system, alongside its supply-chain and business-operation systems, and contributing them into this new entity to serve as the foundational software architecture.
To build out the actual AI infrastructure, Maison Solutions entered into a strategic collaboration in June 2026 with two highly specialized technology partners: SupplyAi and MiniMax. MiniMax is a global leader in multimodal and agentic AI capabilities, specifically purposed for long-context tasks, multimodal reasoning, and enterprise-grade deployment across text, audio, and video. SupplyAi, led by Co-Founder and Chief Technology Officer Tim Zhang (an expert in database systems and applied AI research), is providing the vertical AI product development capabilities.
The objective of Maison AI is to move far beyond simplistic, consumer-facing customer-service chatbots. The food supply chain is entering a massive technology upgrade cycle, plagued by fragmented systems, manual workflows, and highly complex inventory perishability. Maison AI intends to build AI agents that handle inventory management, merchandising, vendor coordination, enterprise resource planning (ERP), and highly complex procurement workflows. CEO John Xu, recently recognized with the Outstanding 50 Asian Americans in Business Award, is taking his deep, granular knowledge of localized demand and culturally specific product assortments and using the physical Maison grocery stores as a live testing environment for these AI models.
The opinion derived from this scenario is one of highly cautious optimism laced with deep fascination. Maison Solutions is essentially attempting to transform from a low-margin, capital-intensive physical grocer into a high-margin software-as-a-service (SaaS) and AI-licensing platform for the broader food retail industry. It is a massive, existential gamble. The market, reacting to the reverse split with a brutal -26.85% weekly drop, is pricing $MSS purely as a failing grocer; it is entirely ignoring the optionality of Maison AI becoming a licensable product for other struggling regional grocery chains. For the risk-tolerant observer, this is a profound structural pivot worth monitoring closely as the company attempts to digitize and automate the physical food supply chain.
Autonomix Medical ($AMIX): Hacking the Human Nervous System
The medical device sector is prone to intense hype cycles, but the recent clinical data emerging from Autonomix Medical ($AMIX) warrants genuine, focused attention. The company is currently trading in the micro-cap depths, recently forced to execute a complex warrant inducement agreement to raise approximately $2.6 million from the exercise of 7,486,605 existing warrants at a heavily discounted $0.35 per share. This dilutive financing, alongside a reverse stock split aimed at maintaining Nasdaq listing compliance, highlights a deeply strained financial reality. The financial optics are undeniably ugly. Yet, the underlying clinical technology has the potential to fundamentally disrupt multi-billion-dollar cardiovascular and pain management markets.
On July 24, 2026, Autonomix announced highly positive, statistically significant results from a preclinical study demonstrating that its proprietary neural sensing platform can accurately detect, localize, and confirm changes in renal neural activity.
The Blind Spot of Renal Denervation
To understand why this preclinical data is a massive breakthrough, one must look at the current state of renal denervation. Renal denervation is a procedure used to treat resistant hypertension by ablating (destroying) sympathetic nerves in the renal artery to lower blood pressure. While the market is massive—featuring heavyweights like Medtronic and ReCor Medical—current procedures are fundamentally flawed.
Currently, physicians perform these ablations entirely blind. They rely strictly on anatomical landmarks, hoping they hit the correct nerves, because there is absolutely no direct physiological feedback during the procedure to confirm the nerve has been successfully neutralized. This lack of precision is precisely why renal denervation clinical trials have historically yielded highly mixed, inconsistent results across patient populations.
Autonomix Medical has solved this exact problem. Their catheter-based technology features a proprietary microchip sensing platform that is deployed endovascularly directly within the renal arteries. In the recent animal-model preclinical study, the catheter successfully recorded and identified neural signals associated with nerve activity across multiple anatomical locations before the ablation.
Crucially, following the targeted ablation, researchers observed a distinct and measurable attenuation (weakening) of those previously detected neural signals. This proves that a surgeon can finally “see” the nervous system in real-time, identify active nerve targets, deliver the radiofrequency therapy, and instantly verify that the nerve is no longer firing.
Expanding the Patent Moat
Adding robust defensibility to this clinical breakthrough, Autonomix also announced the issuance of U.S. Patent No. 12,471,776 on July 23, 2026. Titled “ANS Assessment Systems, Kits, and Methods,” this patent broadly protects their technology for monitoring physiologic signals to evaluate the sympathetic and parasympathetic function of the autonomic nervous system. This dramatically strengthens their intellectual property portfolio against larger medical device competitors attempting to reverse-engineer physiological feedback mechanisms.
While the renal denervation data is groundbreaking, the company’s primary, initial clinical trials are bravely targeting the mitigation of debilitating pain in pancreatic cancer—a condition with massive unmet medical needs and virtually no reliable solutions. Autonomix recently showcased compelling Proof-of-Concept study data at the ASCO Gastrointestinal Cancers Symposium and Digestive Disease Week 2026, demonstrating rapid and durable pain relief across all disease stages. The architecture of this platform supports future expansion into massive markets, including overactive bladder (affecting 37 million Americans), pulmonary, cardiac, and splanchnic nerve-targeted applications.
The emotional takeaway here is one of deep respect for the scientific achievement, heavily tempered by the brutal reality of biotechnology financing. Autonomix has essentially created a highly sensitive stethoscope for the peripheral nervous system, allowing surgeons to hack the body’s electrical grid with precision. It is a brilliant paradigm shift. However, the market is merciless toward pre-revenue, clinical-stage medical device companies facing cash constraints and delisting threats. $AMIX is a high-risk, high-reward proposition where the intrinsic value of the intellectual property and the sheer size of the TAM wildly outpaces the current market capitalization.
Matinas BioPharma ($MTNB): The Ultimate Corporate Metamorphosis
If the public markets are a theater of survival, Matinas BioPharma ($MTNB) just executed the most dramatic, unforeseen plot twist of 2026. This is the story of a clinical-stage biopharmaceutical company that stared directly into the abyss of insolvency, evaluated its options, and chose an entirely different industrial universe over bankruptcy.
For months, Matinas had been flashing severe, terminal warning signs. The company ended Q1 2026 with a paltry $2.4 million in cash against an accumulated deficit of $212.7 million. Operating expenses were running at $1.9 million, resulting in a quarterly cash burn of roughly $1.6 million, leaving the company with a runway measured in weeks, not months. The NYSE American issued a notice of non-compliance regarding stockholders’ equity, demanding a remediation plan. In response, management explicitly attached a “going concern” warning to their SEC filings, halted all clinical development of their lead antifungal candidate, MAT2203 (despite previously agreeing with the FDA on a Phase 3 registration trial design for invasive aspergillosis), slashed the workforce by 80%, and desperately sought a partner or buyer.
On July 23, 2026, a Form 8-K revealed that BTIG, LLC terminated the company’s $50 million At-The-Market (ATM) sales agreement effective immediately, with no penalties. Without an active S-3 shelf and with the ATM canceled, the traditional biotech equity financing routes were completely severed.
The Azurity Sale and the GH Power Reverse Merger
What happened next is a masterclass in corporate shell engineering. On July 13, 2026, Matinas announced two simultaneous, world-altering transactions.
First, they agreed to a definitive stock purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc.—the subsidiary that houses the entirety of the MAT2203 asset and the proprietary Lipid Nano-Crystal (LNC) delivery platform—to Azurity Pharmaceuticals. The terms were a reflection of total desperation: a meager $4.0 million upfront, with up to $17.5 million in potential future milestones and mid-single-digit royalties (of which former Series A holders receive 7.5%). It is a capitulation sale, an asset fire-sale designed purely to extract whatever residual cash value remained from years of intensive R&D.
Second, stripped entirely of its biotech assets, the MTNB corporate shell agreed to a definitive business combination with GH Power Inc.. Through a highly complex plan of arrangement under Section 182 of the Business Corporations Act (Ontario), Matinas will completely exit the pharmaceutical industry and become a publicly traded advanced clean energy and green hydrogen company, operating under a newly formed Ontario holding company expected to be named “GH Power International”.
The valuation metrics of this reverse merger are stark. Matinas is valued at an implied $24,725,274.73 in the transaction, while GH Power commands a $250 million valuation. Upon the expected closing in the fourth quarter of 2026, existing GH Power shareholders will own approximately 91% of the new entity, leaving legacy Matinas stockholders with a heavily diluted 9% stake. The deal structure requires each Matinas common share to convert into 0.1 share of the new Pubco, and is strictly contingent upon GH Power securing at least $15.0 million in gross proceeds via a PIPE financing prior to closing. To keep the lights on until closing, Matinas completed a $575,000 Series D preferred PIPE and a massive warrant inducement yielding $2.6 million.
GH Power brings a completely alien, yet highly compelling, technology to the table: proprietary modular reactors designed to convert scrap metals and water into green hydrogen, high-purity alumina, and usable heat for industrial decarbonization. They anticipate using the $15 million PIPE proceeds to fund commercial project deployment across North America and Europe.
The opinion on this maneuver is one of sheer astonishment and respect for corporate agility. Management navigated an impossible situation—a broken balance sheet, a frozen capital market, and a halted clinical pipeline. Instead of filing for Chapter 11 bankruptcy, which would have wiped out equity holders entirely, they monetized the IP for a few million dollars and sold the public listing shell to a Canadian clean energy firm seeking rapid access to the NYSE American. For current MTNB shareholders, this is a painful 91% dilution event, but it is infinitely better than a zero. The legacy biotech investors are now, suddenly and involuntarily, industrial decarbonization and green hydrogen speculators.
Final Synthesis and Outlook
The equities highlighted in this report share a common, visceral thread: they are undergoing violent, transformative events that the broader market algorithms and passive index funds struggle to accurately price.
$AREC is utilizing a highly unorthodox cash dividend strategy to scream at the market to look at its underlying domestic critical mineral assets, LAD chromatography technology, and massive federal Department of War backing.
$EXYN is attempting to disrupt a notoriously entrenched, inefficient military-industrial complex, eyeing a massive piece of the USAF OIB sustainment budget with Level 4B autonomy, while its stock price reflects total capitulation.
$MSS is engaging in a desperate, highly innovative attempt to outrun crushing physical grocery margins by utilizing multimodal AI models to pivot into an enterprise software provider.
$AMIX holds genuinely disruptive, newly patented medical sensing technology that eliminates the “blind” nature of nervous system ablation, but must aggressively navigate the brutal reality of micro-cap dilution funding.
$MTNB represents the ultimate corporate survival story, shedding its biotech skin and pharmaceutical assets entirely in a complex Ontario reverse merger to become a green hydrogen player.
For the market observer, these scenarios represent the bleeding edge of fundamental research. Trading these equities requires an iron stomach, a deep understanding of the underlying technological shifts, and the ability to look past the immediate, often irrational, market reactions to discern the long-term strategic value being built in the shadows.
DISCLAIMER: Each of Stock Region University LLC’s services, products, and site are available for informational and educational purposes only. None of the information contained in the site constitutes, or is intended to constitute, a recommendation by us of any particular security or trading strategy or a determination by us that any security or trading strategy is suitable for any specific person. We are publishers and educators only. Stock Region University LLC is not a registered investment professional nor financial advisor. This is not investment or financial advice. Always do your own research. You are solely responsible for all investment and financial decisions that you make. All information or advice shown is used for educational purposes only. By participating in this community, you are solely agreeing to this disclaimer. All trade alerts are merely suggestions and do not promise or advertise specific return on investment. Stock Region University LLC does not provide investment, loan services, banking services, tax or legal advice.